NZ504445A - Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive - Google Patents

Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive

Info

Publication number
NZ504445A
NZ504445A NZ504445A NZ50444596A NZ504445A NZ 504445 A NZ504445 A NZ 504445A NZ 504445 A NZ504445 A NZ 504445A NZ 50444596 A NZ50444596 A NZ 50444596A NZ 504445 A NZ504445 A NZ 504445A
Authority
NZ
New Zealand
Prior art keywords
high mobility
contraceptive
genes
nucleic acid
acid sequences
Prior art date
Application number
NZ504445A
Inventor
Jorn Bullerdiek
Original Assignee
Jorn Bullerdiek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jorn Bullerdiek filed Critical Jorn Bullerdiek
Publication of NZ504445A publication Critical patent/NZ504445A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The use of DNA sequences comprising exons of a high mobility group (HMGI) gene or multiple tumour aberration growth (MAG) gene, or a derivative thereof, which has angioneoplasm-influencing activity, for the diagnosis of tumours, is described. Their use for the purposes of contraception and tissue generation is also described.
NZ504445A 1995-12-21 1996-12-20 Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive NZ504445A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19548122A DE19548122A1 (en) 1995-12-21 1995-12-21 Nucleic acid sequences of high mobility group protein genes and uses thereof

Publications (1)

Publication Number Publication Date
NZ504445A true NZ504445A (en) 2002-08-28

Family

ID=7781000

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ504445A NZ504445A (en) 1995-12-21 1996-12-20 Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive

Country Status (7)

Country Link
EP (1) EP0870024A2 (en)
JP (3) JP2000504933A (en)
AU (1) AU1870597A (en)
CA (1) CA2239682A1 (en)
DE (1) DE19548122A1 (en)
NZ (1) NZ504445A (en)
WO (1) WO1997023611A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19824230A1 (en) * 1998-05-29 1999-12-02 Starzinski Powitz Anna New endometriosis-associated gene
DE19904514A1 (en) * 1999-02-04 2000-08-10 Joern Bullerdiek Antiviral agent, e.g. vaccine, antibody, agent that inhibits viral replication, transcription or translation, useful for preventing or treating tumors (or conditions which may become tumorous) associated with viral infections
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
AU7899300A (en) * 1999-10-18 2001-04-30 Shanghai Bio Road Gene Technology Ltd. A novel polypeptide - human high mobility group protein 13 and a polynucleotide encoding the same
CN1300762A (en) * 1999-12-23 2001-06-27 复旦大学 Polypeptide-high-migration component protein family 11 and polynucleotide for codign this polypeptide
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
EP1453531B1 (en) * 2001-12-19 2008-05-14 Alcedo Biotech GmbH Use of hmgb proteins and nucleic acids that code therefor
EP1519957B1 (en) * 2002-07-03 2009-03-04 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
JP2006517537A (en) * 2003-01-03 2006-07-27 アルケド バイオテック ゲーエムベーハー Use of DNA-binding proteins
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CN1878793A (en) 2003-09-11 2006-12-13 鉴定医疗有限公司 Monoclonal antibodies against HMGB1
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
WO2007001422A2 (en) 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
AU2006330807A1 (en) 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of HMBG1 and/or rage and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5279941A (en) * 1992-06-12 1994-01-18 Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation
EP0727487A1 (en) * 1995-02-17 1996-08-21 K.U. Leuven Research & Development Multiple-tumor aberrant growth genes

Also Published As

Publication number Publication date
CA2239682A1 (en) 1997-07-03
WO1997023611A2 (en) 1997-07-03
JP2010029207A (en) 2010-02-12
WO1997023611A3 (en) 1997-10-02
DE19548122A1 (en) 1997-06-26
JP2000504933A (en) 2000-04-25
JP2007312778A (en) 2007-12-06
EP0870024A2 (en) 1998-10-14
AU1870597A (en) 1997-07-17

Similar Documents

Publication Publication Date Title
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
Beal et al. Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation
HUP0004728A1 (en) Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor
ATE323169T1 (en) PLASMID FOR ADMINISTRATION OF NUCLEIC ACIDS AND METHOD OF USE
AU3368497A (en) Human dnase i hyperactive variants
WO1991004316A3 (en) Ciliary neurotrophic factor
CA2338541A1 (en) Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy
NO973685L (en) Multi-tumor aberrant growth genes
MX9708854A (en) Gene therapy for effector cell regulation.
CA2284859A1 (en) Nucleic acid molecule for a human skeletal muscle-specific receptor
MY102918A (en) Purified antineoplaston fractions and methods of treating neoplastic disease.
DE69635349D1 (en) NUCLEOTIDE SEQUENCES, PROTEINS, MEDICAMENTS AND DIAGNOSIS AGENTS FOR THE USE OF CANCER TREATMENT
WO1999015643A3 (en) ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE
DE69834727D1 (en) 5 'ESTS FOR SECRETED PROTEINS EXPOSED IN DIFFERENT TISSUE
HK1002531A1 (en) New tumor diagnosing or therapeutical probe
EP1169441B8 (en) Pharmaceutical compositions for the treatment of heart failure
WO1995034669A3 (en) Retroviral gene therapy vectors and therapeutic methods based thereon
HUP0201868A2 (en) Antisense therapy for hormone-regulated tumors
WO2000008157A3 (en) Human anion transporter genes atnov
AU2001233957A1 (en) Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression
DE19681032D2 (en) Gene therapy nucleic acid construct, its production and use for the treatment of heart diseases
KR100488038B1 (en) New bpc peptide salts with organo-protective activity the process for their preparation and their use in therapy
EP0527941A4 (en)
ES2194794T3 (en) DENDRIMEROS PHOSPHORATED AS TRANSFER AGENTS.
DE69730967D1 (en) Human dnase ii

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired